Lista de obras - Hana Klamová - Dominio Público Uruguay

A short note on the nuclear diameter in human early granulocytic progenitors.

artículo científico publicado en 2006

AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome

artículo científico publicado en 2018

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

artículo científico publicado en 2020

Are microproerythroblasts in human bone marrow real or artefacts? A cytochemical note

artículo científico publicado en 2005

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

artículo científico publicado en 2010

BCR-ABL mutations in chronic myeloid leukemia–Not only detection

scientific article published on 01 August 2008

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

artículo científico publicado en 2018

Bmi-1over-expression plays a secondary role in chronic myeloid leukemia transformation

scientific article published on 01 April 2007

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma

artículo científico publicado en 2008

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.

artículo científico publicado en 2005

Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment

artículo científico publicado en 2010

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.

artículo científico publicado en 2015

Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study ⬇️

scholarly article

Complex chromosomal rearrangements in patients with chronic myeloid leukemia

scientific article published on 01 July 2006

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

artículo científico publicado en 2010

Control genes in international standardization of real-time RT-PCR for BCR-ABL.

artículo científico publicado en 2008

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

artículo científico publicado en 2013

DNA Based Detection and Quantification of BCR-ABL1 Gene Using Patient-Specific qPCR and Droplet Digital PCR Tests in Chronic Myeloid Leukemia ⬇️

artículo científico publicado en 2015

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

artículo científico publicado en 2008

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

artículo científico publicado en 2010

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

artículo científico publicado en 2020

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors

artículo científico publicado en 2024

Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase

artículo científico publicado en 2004

Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis.

artículo científico publicado en 2005

Effect of the duration and quality of peripheral blood sample storage on the results of qualitative and quantitative BCR-ABL transcript analyses in patients with CML.

artículo científico publicado en 2011

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

artículo científico publicado en 2013

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

artículo científico publicado en 2011

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

artículo científico publicado en 2013

Expression of Four Major WT1 Splicing Variants in AML and CML: Development of Quantitative Real-Time PCRs and Preliminary Results in Patient Samples. ⬇️

artículo científico publicado en 2009

Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs.

artículo científico publicado en 2012

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

artículo científico publicado en 2016

Expression patterns of microRNAs associated with CML phases and their disease related targets

artículo científico publicado en 2011

Gene expression profiles of two accelerations in a CML patient.

artículo científico publicado en 2005

Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea

artículo científico publicado en 2002

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

artículo científico publicado en 2017

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia ⬇️

artículo científico publicado en 2019

HSP90 Chaperone – An Important Player in CML: Study At RNA and Protein Level ⬇️

artículo científico publicado en 2011

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain

artículo científico publicado en 2008

Hsp90 - a potential prognostic marker in CML.

artículo científico publicado en 2012

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

artículo científico publicado en 2011

Imatinib mesylate affects tyrosine kinase activity in both leukemic and normal primary mononuclear blood cells

artículo científico publicado en 2006

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

artículo científico publicado en 2022

In Vitro Sensitivity to Tyrosine Kinase Inhibitors Is One of Possible Predictive Parameters for Therapy Switch In Patients with Chronic Myeloid Leukemia ⬇️

artículo científico publicado en 2010

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

artículo científico publicado en 2011

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

artículo científico publicado en 2018

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

artículo científico publicado en 2016

Intracellular Cytokines Produced by Stimulated CD3+ Cells from Chronic Myeloid Leukemia Patients.

artículo científico publicado en 2017

Kynurenine and uric acid levels in chronic myeloid leukemia patients.

artículo científico publicado en 2015

MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?

artículo científico publicado en 2011

Microscopic notes on the perinucleolar chromatin region in immature and mature human B-leukemia lymphocytes.

artículo científico publicado en 2013

Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain ⬇️

scholarly article

N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia.

artículo científico publicado en 2012

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2014

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

artículo científico publicado en 2016

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

artículo científico publicado en 2013

Nucleolar and cytoplasmic RNA density-concentration in leukemia granulocytic progenitors in human bone marrow biopsies: A short cytochemical note

artículo científico publicado en 2009

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment ⬇️

scholarly article

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

artículo científico publicado en 2010

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries ⬇️

scholarly article

Predictive value of serum cytokine levels in chronic myeloid leukemia patients

artículo científico publicado en 2016

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.

artículo científico publicado en 2009

SNPs in the Promoter of the Gene Encoding Transmembrane Transporter SLC22A4 (hOCTN1) Are Significantly Associated with an Alteration of Gene Expression and with Resistance to the Imatinib Treatment in Chronic Myeloid Leukemia ⬇️

scholarly article

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

artículo científico publicado en 2021

Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo

artículo científico publicado en 2016

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

artículo científico publicado en 2021

Supportive Methods for Testing CML Progression in Addition to BCR-ABL Transcript Monitoring – What to Do If BCR-ABL Monitoring doesn't Work? ⬇️

artículo científico publicado en 2011

Targeting of gene expression by siRNA in CML primary cells

artículo científico publicado en 2006

The Musashi 2 mRNA Expression in the Course of CML. ⬇️

scholarly article

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2024

The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.

artículo científico publicado en 2006

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

artículo científico publicado en 2011

To the intranucleolar translocation of AgNORs in leukemic early granulocytic and plasmacytic precursors.

artículo científico publicado en 2005

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy ⬇️

scholarly article

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

artículo científico publicado en 2013

Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and Megakaryocytic Dysplasia

artículo científico publicado en 2011

Vascular adverse events in chronic myeloid leukaemia patients during tyrosine kinase inhibitor therapy in daily clinical practice – analysis from the INFINITY database

artículo científico publicado en 2023

WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance.

artículo científico publicado en 2009

Lista de obras de Hana Klamová

A short note on the nuclear diameter in human early granulocytic progenitors.

AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Are microproerythroblasts in human bone marrow real or artefacts? A cytochemical note

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

BCR-ABL mutations in chronic myeloid leukemia–Not only detection

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

Bmi-1over-expression plays a secondary role in chronic myeloid leukemia transformation

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.

Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.

Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study ⬇️

Complex chromosomal rearrangements in patients with chronic myeloid leukemia

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

Control genes in international standardization of real-time RT-PCR for BCR-ABL.

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

DNA Based Detection and Quantification of BCR-ABL1 Gene Using Patient-Specific qPCR and Droplet Digital PCR Tests in Chronic Myeloid Leukemia ⬇️

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors

Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase

Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis.

Effect of the duration and quality of peripheral blood sample storage on the results of qualitative and quantitative BCR-ABL transcript analyses in patients with CML.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

Expression of Four Major WT1 Splicing Variants in AML and CML: Development of Quantitative Real-Time PCRs and Preliminary Results in Patient Samples. ⬇️

Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs.

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

Expression patterns of microRNAs associated with CML phases and their disease related targets

Gene expression profiles of two accelerations in a CML patient.

Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia ⬇️

HSP90 Chaperone – An Important Player in CML: Study At RNA and Protein Level ⬇️

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain

Hsp90 - a potential prognostic marker in CML.

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Imatinib mesylate affects tyrosine kinase activity in both leukemic and normal primary mononuclear blood cells

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

In Vitro Sensitivity to Tyrosine Kinase Inhibitors Is One of Possible Predictive Parameters for Therapy Switch In Patients with Chronic Myeloid Leukemia ⬇️

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Intracellular Cytokines Produced by Stimulated CD3+ Cells from Chronic Myeloid Leukemia Patients.

Kynurenine and uric acid levels in chronic myeloid leukemia patients.

MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?

Microscopic notes on the perinucleolar chromatin region in immature and mature human B-leukemia lymphocytes.

Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain ⬇️

N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia.

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

Nucleolar and cytoplasmic RNA density-concentration in leukemia granulocytic progenitors in human bone marrow biopsies: A short cytochemical note

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment ⬇️

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries ⬇️

Predictive value of serum cytokine levels in chronic myeloid leukemia patients

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.

SNPs in the Promoter of the Gene Encoding Transmembrane Transporter SLC22A4 (hOCTN1) Are Significantly Associated with an Alteration of Gene Expression and with Resistance to the Imatinib Treatment in Chronic Myeloid Leukemia ⬇️

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

Supportive Methods for Testing CML Progression in Addition to BCR-ABL Transcript Monitoring – What to Do If BCR-ABL Monitoring doesn't Work? ⬇️

Targeting of gene expression by siRNA in CML primary cells

The Musashi 2 mRNA Expression in the Course of CML. ⬇️

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

To the intranucleolar translocation of AgNORs in leukemic early granulocytic and plasmacytic precursors.

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy ⬇️

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and Megakaryocytic Dysplasia

Vascular adverse events in chronic myeloid leukaemia patients during tyrosine kinase inhibitor therapy in daily clinical practice – analysis from the INFINITY database

WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance.